Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INVITAE CORPORATION

(NVTA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Invitae : Morgans rates VHT as Add

07/27/2021 | 08:31pm EDT

Morgans assesses momentum continues to build with record cash receipts and growing annual recurring revenue (ARR), after Volpara Health Technologies posted its first quarter cashflow report.

The broker highlights the focus on risk assessment and genetics has been enhanced with the recent CRA Health acquisition and collaboration with Invitae Corporation.

Morgans makes no changes to forecasts and maintains its $1.87 target price and Add rating.

Sector: Health Care Equipment & Services.

Target price is $1.87.Current Price is $1.14. Difference: $0.73 - (brackets indicate current price is over target). If VHT meets the Morgans target it will return approximately 39% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2021 Acquisdata Pty Ltd., source FN Arena

All news about INVITAE CORPORATION
09/09VC DAILY : Digital Health Is Booming, but VC Doesn't See a Bubble Forming
DJ
09/07INVITAE : Ciitizen Announcement Conference Call Presentation
PU
09/07INVITAE : — Combination to bring together the power of genomic and clinical informati..
PU
09/07INVITAE CORP : Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Eve..
AQ
09/07INVITAE : to Acquire Consumer Health Tech Company Ciitizen in $325 Million Deal
MT
09/07INVITAE : to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to ..
PR
09/07Invitae Corporation entered into definitive agreement to acquire Ciitizen Corporation f..
CI
09/01INVITAE : to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
PR
08/19INVITAE : Significant Insider Sales in Shares of Invitae (NVTA) Extends the Selling Trend ..
MT
08/18INSIDER TRENDS : 90-Day Insider Selling Trend Extended at Invitae
MT
More news
Analyst Recommendations on INVITAE CORPORATION
More recommendations
Financials (USD)
Sales 2021 484 M - -
Net income 2021 -530 M - -
Net Debt 2021 342 M - -
P/E ratio 2021 -12,6x
Yield 2021 -
Capitalization 6 996 M 6 996 M -
EV / Sales 2021 15,2x
EV / Sales 2022 11,0x
Nbr of Employees 2 600
Free-Float 96,9%
Chart INVITAE CORPORATION
Duration : Period :
Invitae Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVITAE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 32,19 $
Average target price 40,44 $
Spread / Average Target 25,6%
EPS Revisions
Managers and Directors
Sean Emerson George Chairman, President & Chief Executive Officer
Roxi Wen Chief Financial Officer
Robert Nussbaum Chief Medical Officer
Eric Olivares Chief Science Officer
Layton Wedgeworth Chief Technology Officer
Sector and Competitors